# Clinical Outcomes of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-cell Therapy in Patients With Antecedent Mycobacterium avium Complex Pulmonary Disease: A Case Series of 8 Patients

## TL;DR

Eight patients with a specific lung disease successfully underwent cancer treatments without complications from their lung condition.

## Contribution

This case series demonstrates that a specific lung disease does not prevent hematopoietic cell transplantation or CAR-T therapy.

## Key findings

- Eight patients with Mycobacterium avium complex pulmonary disease underwent HCT or CAR-T therapy.
- None of the patients developed complications from their lung disease after treatment.
- The results suggest that this lung condition should not exclude patients from receiving these therapies.

## Abstract

In this single-center case series, we identified 8 patients with nontuberculous mycobacterial pulmonary disease (NTM-PD), all due to Mycobacterium avium complex, who underwent hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy. None, including 3 without NTM-PD treatment before HCT/CAR-T therapy, developed any apparent complications from NTM-PD. This experience suggests that NTM-PD should not preclude HCT/CAR-T therapy.